TABLE 2.
β-Lactam and glycopeptide resistance of L. monocytogenes LO28 wild-type and ΔcesR, ΔcesK, Δlmo0443, Δlmo1416, Δlmo2210, and Δlmo2812 mutant strains
| Substance (amt [μg]) | Avg zone of inhibition (mm) ± SDa
|
||||||
|---|---|---|---|---|---|---|---|
| wt | ΔcesR mutant | ΔcesK mutant | Δlmo0443 mutant | Δlmo1416 mutant | Δlmo2210 mutant | Δlmo2812 mutant | |
| Cefuroxime (30) | 19.2 ± 0.8 | 31.0 ± 0.5* | 28.7 ± 0.3* | 18.2 ± 0.8 | 30.2 ± 0.8* | 19.3 ± 1.3 | 17.5 ± 0.5 |
| Ampicillin (10) | 33.5 ± 0.5 | 36.2 ± 0.3* | 36.3 ± 0.8* | 30.8 ± 0.8 | 37.0 ± 0.5* | 33.3 ± 0.3 | 33.8 ± 0.3 |
| Vancomycin (30) | 22.8 ± 0.3 | 23.8 ± 0.3 | 24.3 ± 0.8 | 23.0 ± 1.0 | 22.8 ± 0.3 | 20.8 ± 0.3* | 19.5 ± 0.5* |
| Teicoplanin (30) | 22.5 ± 0.5 | 22.2 ± 0.3 | 21.8 ± 0.3 | 21.7 ± 0.8 | 20.8 ± 0.3 | 19.5 ± 0,0* | 18.5 ± 0.9* |
a
The results are averages of triplicate experiments. *, significant difference (P < 0.01) between the mutant strain and the wild type.